Company research
Absci Corp
CIK 1672688Updated Sep 24, 2026
SecurityABSI · NASDAQ · equity
Name history
AbSci, LLC · through Dec 19, 2019
ABSI price & chart
Loading TradingView…
NASDAQ:ABSI on TradingView ↗About the company
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential.
In the news
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 ↗
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
4 filing
4 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 216,297,000Source | 213,608,000Source | 217,298,000Source | 321,008,000Source |
| GoodwillUSD | — | — | 0Source | 21,335,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 41,514,000Source | 44,883,000Source | 48,253,000Source | 51,622,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,025,000Source | 41,213,000Source | 72,362,000Source | 59,955,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | — | — |
| Assets, CurrentUSD | 149,573,000Source | 133,831,000Source | 120,578,000Source | 186,863,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,281,000Source | 5,459,000Source | 4,537,000Source | 5,859,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,914,000Source | 3,968,000Source | 4,490,000Source | 5,319,000Source |
| Other Assets, NoncurrentUSD | 383,000Source | 705,000Source | 1,537,000Source | 1,282,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 26,848,000Source | 34,475,000Source | 41,122,000Source | 46,594,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 15,000Source | 12,000Source | 9,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -624,784,000Source | -509,601,000Source | -406,495,000Source | -295,929,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 591,000Source | -4,000Source | -37,000Source | -120,000Source |
| Stockholders' Equity Attributable to ParentUSD | 189,449,000Source | 179,133,000Source | 176,176,000Source | 274,414,000Source |
| Additional Paid in Capital, Common StockUSD | 813,627,000Source | 688,726,000Source | 582,699,000Source | 570,454,000Source |
| Liabilities and EquityUSD | 216,297,000Source | 213,608,000Source | 217,298,000Source | 321,008,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 22,765,000Source | 28,656,000Source | 29,558,000Source | 30,270,000Source |
| Operating Lease, Liability, CurrentUSD | 1,805,000Source | 1,608,000Source | 1,679,000Source | 1,690,000Source |
| Accounts Payable, CurrentUSD | 2,756,000Source | 3,529,000Source | 1,503,000Source | 2,412,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,624,000Source | 4,429,000Source | 5,643,000Source | 7,317,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 186,000Source | 238,000Source |
| Other Liabilities, NoncurrentUSD | 1,023,000Source | 133,000Source | 33,000Source | 35,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | 6,842,000Source | 19,303,000Source | 20,481,000Source |
| Deferred Tax Liabilities, NetUSD | 23,000Source | 121,000Source | 186,000Source | 238,000Source |
| Long-term DebtUSD | — | 3,990,000Source | 7,918,000Source | 10,930,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 11,742,000Source | 13,389,000Source | 13,999,000Source | 13,037,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 18,321,000Source | 19,452,000Source | 11,416,000Source | 12,540,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | -2,239,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | 1,094,000Source | 2,026,000Source | -786,000Source | -533,000Source |
| Deferred Income Tax Expense (Benefit)USD | -98,000Source | -65,000Source | -52,000Source | -505,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -92,925,000Source | -72,402,000Source | -64,636,000Source | -81,339,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 0Source | 8,000,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -50,160,000Source | -41,577,000Source | 81,944,000Source | -126,982,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,107,000Source | 404,000Source | 860,000Source | 16,175,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 105,949,000Source | 82,526,000Source | -4,483,000Source | 5,237,000Source |
| Repayments of Long-term DebtUSD | 3,117,000Source | 3,388,000Source | 3,012,000Source | 4,651,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -37,136,000Source | -31,453,000Source | 12,825,000Source | -203,084,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 21,078,000Source | 58,214,000Source | 89,667,000Source | 76,842,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 178,000Source | 561,000Source | 970,000Source | 895,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 18,352,000Source | 19,469,000Source | 11,454,000Source | 12,658,000Source |
| Amortization of Intangible AssetsUSD | 3,400,000Source | 3,400,000Source | 3,400,000Source | 3,400,000Source |
| DepreciationUSD | 8,400,000Source | 10,000,000Source | 10,600,000Source | 9,700,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | 900,000Source | — | — |
| GoodwillUSD | — | — | 0Source | 21,335,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 21,335,000Source | — |
| Income Tax Expense (Benefit)USD | 69,000Source | 70,000Source | 100,000Source | -461,000Source |
| InterestExpenseNonoperatingUSD | 209,000Source | 565,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -115,183,000Source | -103,106,000Source | -110,566,000Source | -104,904,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -110,566,000Source | -104,904,000Source |
| Nonoperating Income (Expense)USD | 5,203,000Source | 5,852,000Source | 5,049,000Source | 1,385,000Source |
| Operating ExpensesUSD | 123,117,000Source | 113,422,000Source | 121,233,000Source | 112,497,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | 400,000Source |
| Other Nonoperating Income (Expense)USD | 5,412,000Source | 6,417,000Source | 6,059,000Source | 2,357,000Source |
| Proceeds from Issuance of Common StockUSD | 105,835,000Source | — | 862,000Source | 656,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 69,500,000Source | 177,100,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,800,000Source | 4,534,000Source | 5,718,000Source | 4,529,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 4,534,000Source | 5,718,000Source | 5,747,000Source |
| Selling, General and Administrative ExpenseUSD | 35,058,000Source | 36,174,000Source | 37,832,000Source | 40,552,000Source |
| Operating Income (Loss)USD | -120,317,000Source | -108,888,000Source | -115,515,000Source | -106,750,000Source |
| Other Nonoperating Income (Expense)USD | 5,412,000Source | 6,417,000Source | 6,059,000Source | 2,357,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -115,114,000Source | -103,036,000Source | -110,466,000Source | -105,365,000Source |
| Income Tax Expense (Benefit)USD | 69,000Source | 70,000Source | 100,000Source | -461,000Source |
| Net Income (Loss) Attributable to ParentUSD | -115,183,000Source | -103,106,000Source | -110,566,000Source | -104,904,000Source |
| Earnings Per Share, BasicUSD per share | -0.84Source | -0.94Source | -1.2Source | -1.15Source |
| Earnings Per Share, DilutedUSD per share | -0.84Source | -0.94Source | -1.2Source | -1.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 136,776,885Source | 110,239,870Source | 92,028,016Source | 90,845,629Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 136,776,885Source | 110,239,870Source | 92,028,016Source | 90,845,629Source |
| Interest Expense (non-operating)USD | 209,000Source | 565,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 3,400,000Source | 3,400,000Source | 3,400,000Source | 3,400,000Source |
| Current Income Tax Expense (Benefit)USD | 167,000Source | 135,000Source | 152,000Source | 44,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | 900,000Source | — | — |
| Goodwill, Impairment LossUSD | — | 0Source | 21,335,000Source | — |
| Income (Loss) Attributable to Parent, before TaxUSD | -115,114,000Source | -103,036,000Source | -110,466,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -117,796,000Source | -104,682,000Source | -112,788,000Source | — |
| Interest ExpenseUSD | — | — | 1,010,000Source | 972,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -110,566,000Source | -104,904,000Source |
| Nonoperating Income (Expense)USD | 5,203,000Source | 5,852,000Source | 5,049,000Source | 1,385,000Source |
| Operating ExpensesUSD | 123,117,000Source | 113,422,000Source | 121,233,000Source | 112,497,000Source |
| Research and Development ExpenseUSD | 81,418,000Source | 63,859,000Source | 48,067,000Source | 58,908,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,800,000Source | 4,534,000Source | 5,718,000Source | 4,529,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | 0Source |
Filing attachments
d139233dex991.htm · 8-K · 2026-06-24
EX-99.1 4 d139233dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201 TM across androgenetic alopecia and endometriosis VANCOUVER, Wash. and NEW YORK, June 24, 2026 - Absci Corporat…
Read attachment ↗d65613dex991.htm · 8-K · 2025-07-25
EX-99.1 4 d65613dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Absci Announces Proposed Public Offering of Common Stock VANCOUVER, WA - July 24, 2025 - Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten public offering of $50 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purcha…
Read attachment ↗d65613dex992.htm · 8-K · 2025-07-25
EX-99.2 5 d65613dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Absci Announces Pricing of Public Offering of Common Stock VANCOUVER, WA - July 24, 2025 - Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting dis…
Read attachment ↗